Which has preferable earnings and valuation, PGEN or PCVX?

Precigen has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Precigen $9.68M 270.88 -$250.64M -$1.04 N/A Vaxcyte N/A N/A -$766.63M -$7.63 N/A

Is PGEN or PCVX more profitable?

Vaxcyte has a net margin of 0.00% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Precigen -183.98% 423.75% 84.39% Vaxcyte N/A -37.56% -33.62%

Does the media favor PGEN or PCVX?

In the previous week, Precigen had 2 more articles in the media than Vaxcyte. MarketBeat recorded 14 mentions for Precigen and 12 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.77 beat Precigen's score of 0.58 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 11 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better earnings and valuation, IMVT or PGEN?

Precigen has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunovant N/A N/A -$505.61M -$2.82 N/A Precigen $9.68M 270.88 -$250.64M -$1.04 N/A

Is IMVT or PGEN more profitable?

Immunovant has a net margin of 0.00% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -69.59% -62.49% Precigen -183.98% 423.75% 84.39%

Does the media prefer IMVT or PGEN?

In the previous week, Precigen had 6 more articles in the media than Immunovant. MarketBeat recorded 14 mentions for Precigen and 8 mentions for Immunovant. Immunovant's average media sentiment score of 1.51 beat Precigen's score of 0.58 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Precigen 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to APGE or PGEN?

In the previous week, Precigen had 5 more articles in the media than Apogee Therapeutics. MarketBeat recorded 14 mentions for Precigen and 9 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.61 beat Precigen's score of 0.58 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Precigen 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, PGEN or ALKS?

Alkermes has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Precigen $9.68M 270.88 -$250.64M -$1.04 N/A Alkermes $1.48B 5.51 $241.66M $0.38 127.62

Is PGEN or ALKS more profitable?

Alkermes has a net margin of 3.96% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Alkermes' return on equity. Company Net Margins Return on Equity Return on Assets Precigen -183.98% 423.75% 84.39% Alkermes 3.96% 4.15% 2.19%

Does the media prefer PGEN or ALKS?

In the previous week, Precigen had 10 more articles in the media than Alkermes. MarketBeat recorded 14 mentions for Precigen and 4 mentions for Alkermes. Alkermes' average media sentiment score of 0.75 beat Precigen's score of 0.58 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alkermes 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, PGEN or IBRX?

Precigen has higher earnings, but lower revenue than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Precigen $9.68M 270.88 -$250.64M -$1.04 N/A ImmunityBio $113.29M 80.69 -$351.40M -$0.97 N/A

Is PGEN or IBRX more profitable?

Precigen has a net margin of -183.98% compared to ImmunityBio's net margin of -598.55%. Precigen's return on equity of 423.75% beat ImmunityBio's return on equity. Company Net Margins Return on Equity Return on Assets Precigen -183.98% 423.75% 84.39% ImmunityBio -598.55% N/A -51.65%

Does the media prefer PGEN or IBRX?

In the previous week, Precigen had 5 more articles in the media than ImmunityBio. MarketBeat recorded 14 mentions for Precigen and 9 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.76 beat Precigen's score of 0.58 indicating that ImmunityBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Precigen (PGEN) Competitors

$7.36 -0.07 (-0.88%)

As of 01:01 PM Eastern

Compare

PGEN vs. PCVX, IMVT, APGE, ALKS, and IBRX

Should you buy Precigen stock or one of its competitors? Precigen's main competitors and comparable companies include Vaxcyte (PCVX), Immunovant (IMVT), Apogee Therapeutics (APGE), Alkermes (ALKS), and ImmunityBio (IBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Precigen compare to Vaxcyte?

Precigen (NASDAQ:PGEN) and Vaxcyte (NASDAQ:PCVX) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

33.5% of Precigen shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 41.4% of Precigen shares are held by insiders. Comparatively, 3.3% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Vaxcyte has a net margin of 0.00% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-183.98%	423.75%	84.39%
Vaxcyte	N/A	-37.56%	-33.62%

Precigen has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	270.88	-$250.64M	-$1.04	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A

Precigen presently has a consensus price target of $14.50, suggesting a potential upside of 97.14%. Vaxcyte has a consensus price target of $86.00, suggesting a potential upside of 40.11%. Given Precigen's stronger consensus rating and higher possible upside, analysts clearly believe Precigen is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Vaxcyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Precigen has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market.

In the previous week, Precigen had 2 more articles in the media than Vaxcyte. MarketBeat recorded 14 mentions for Precigen and 12 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.77 beat Precigen's score of 0.58 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	11 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Precigen beats Vaxcyte on 11 of the 16 factors compared between the two stocks.

How does Precigen compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Precigen (NASDAQ:PGEN) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

In the previous week, Precigen had 6 more articles in the media than Immunovant. MarketBeat recorded 14 mentions for Precigen and 8 mentions for Immunovant. Immunovant's average media sentiment score of 1.51 beat Precigen's score of 0.58 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Precigen	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Precigen has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Precigen	$9.68M	270.88	-$250.64M	-$1.04	N/A

Immunovant presently has a consensus target price of $44.00, indicating a potential upside of 0.62%. Precigen has a consensus target price of $14.50, indicating a potential upside of 97.14%. Given Precigen's stronger consensus rating and higher probable upside, analysts clearly believe Precigen is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55
Precigen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Immunovant has a net margin of 0.00% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Precigen	-183.98%	423.75%	84.39%

47.1% of Immunovant shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 1.9% of Immunovant shares are held by insiders. Comparatively, 41.4% of Precigen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Immunovant has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, Precigen has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market.

Summary

Precigen beats Immunovant on 12 of the 16 factors compared between the two stocks.

How does Precigen compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Precigen (NASDAQ:PGEN) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Apogee Therapeutics has a net margin of 0.00% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-29.88%	-28.08%
Precigen	-183.98%	423.75%	84.39%

79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by insiders. Comparatively, 41.4% of Precigen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Apogee Therapeutics presently has a consensus target price of $124.43, suggesting a potential downside of 7.80%. Precigen has a consensus target price of $14.50, suggesting a potential upside of 97.14%. Given Precigen's stronger consensus rating and higher probable upside, analysts clearly believe Precigen is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.20
Precigen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Precigen had 5 more articles in the media than Apogee Therapeutics. MarketBeat recorded 14 mentions for Precigen and 9 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.61 beat Precigen's score of 0.58 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Precigen	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Precigen has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A
Precigen	$9.68M	270.88	-$250.64M	-$1.04	N/A

Apogee Therapeutics has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, Precigen has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market.

Summary

Precigen beats Apogee Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Precigen compare to Alkermes?

Precigen (NASDAQ:PGEN) and Alkermes (NASDAQ:ALKS) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

Alkermes has a net margin of 3.96% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Alkermes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-183.98%	423.75%	84.39%
Alkermes	3.96%	4.15%	2.19%

Precigen presently has a consensus price target of $14.50, suggesting a potential upside of 97.14%. Alkermes has a consensus price target of $54.56, suggesting a potential upside of 12.51%. Given Precigen's stronger consensus rating and higher probable upside, analysts plainly believe Precigen is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

Precigen has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, Alkermes has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

Alkermes has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	270.88	-$250.64M	-$1.04	N/A
Alkermes	$1.48B	5.51	$241.66M	$0.38	127.62

In the previous week, Precigen had 10 more articles in the media than Alkermes. MarketBeat recorded 14 mentions for Precigen and 4 mentions for Alkermes. Alkermes' average media sentiment score of 0.75 beat Precigen's score of 0.58 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alkermes	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

33.5% of Precigen shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 41.4% of Precigen shares are owned by insiders. Comparatively, 4.6% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Precigen and Alkermes tied by winning 8 of the 16 factors compared between the two stocks.

How does Precigen compare to ImmunityBio?

Precigen (NASDAQ:PGEN) and ImmunityBio (NASDAQ:IBRX) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

In the previous week, Precigen had 5 more articles in the media than ImmunityBio. MarketBeat recorded 14 mentions for Precigen and 9 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.76 beat Precigen's score of 0.58 indicating that ImmunityBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Precigen has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, meaning that its share price is 97% less volatile than the broader market.

Precigen currently has a consensus target price of $14.50, suggesting a potential upside of 97.14%. ImmunityBio has a consensus target price of $14.20, suggesting a potential upside of 64.64%. Given Precigen's stronger consensus rating and higher possible upside, analysts plainly believe Precigen is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Precigen has higher earnings, but lower revenue than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	270.88	-$250.64M	-$1.04	N/A
ImmunityBio	$113.29M	80.69	-$351.40M	-$0.97	N/A

Precigen has a net margin of -183.98% compared to ImmunityBio's net margin of -598.55%. Precigen's return on equity of 423.75% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-183.98%	423.75%	84.39%
ImmunityBio	-598.55%	N/A	-51.65%

33.5% of Precigen shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 41.4% of Precigen shares are held by company insiders. Comparatively, 66.1% of ImmunityBio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Precigen beats ImmunityBio on 12 of the 17 factors compared between the two stocks.

Get Precigen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PGEN vs. The Competition

Export

Metric	Precigen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.63B	$4.01B	$7.23B	$12.93B
Dividend Yield	N/A	3.63%	2.54%	11.02%
P/E Ratio	-7.08	11.52	272.47	24.30
Price / Sales	270.88	1,315.39	609.96	79.82
Price / Cash	N/A	108.37	79.89	53.65
Price / Book	61.29	16.68	13.10	6.27
Net Income	-$250.64M	-$22.76M	$3.46B	$347.96M
7 Day Performance	-1.14%	3.68%	2.09%	1.55%
1 Month Performance	35.70%	12.00%	8.27%	4.78%
1 Year Performance	60.24%	59.00%	26.53%	17.14%

Precigen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PGEN Precigen	3.8942 of 5 stars	$7.36 -0.9%	$14.50 +97.1%	+74.2%	$2.63B	$9.68M	N/A	190	Insider Trade
PCVX Vaxcyte	2.5178 of 5 stars	$60.22 +3.7%	$86.00 +42.8%	+102.0%	$8.64B	N/A	N/A	160	Positive News
IMVT Immunovant	1.1012 of 5 stars	$43.71 +4.5%	$44.00 +0.7%	+191.0%	$8.64B	N/A	N/A	120	News Coverage Positive News Analyst Forecast
APGE Apogee Therapeutics	1.6587 of 5 stars	$134.59 +0.0%	$124.43 -7.5%	+256.4%	$8.37B	N/A	N/A	91	News Coverage Positive News
ALKS Alkermes	2.3472 of 5 stars	$49.85 +1.6%	$54.56 +9.5%	+69.6%	$8.23B	$1.48B	131.19	2,050

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PGEN) was last updated on 8/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Precigen (PGEN) Competitors